Unless otherwise noted, speakers have nothing to disclose.

Moderators

Daniela Molena, MD
Disclosure: Astra Zeneca: Steering committee; Boston Scientific: Consultant; Edwards Lifesciences, Medtronic, AtriCure, Abbott, CryoLife, Johnson and Johnson, ClearFlow: Consultant; Intuitive Surgical: Consultant (Status: Terminated); ravel support for study (Status: Terminated); Urogen: Consultant (Status: Terminated)
Siva Raja, MD, PhD
Disclosure: Bristol Myers Squibb: Speaker's Bureau; Chromacode: Royalties; Smiths Medical: Advisory Board

Presentations

1. Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): a multicenter, phase 2 study
   Presenter: Jingpei Li, MD, PhD
2. Neoadjuvant Immunotherapy and Chemoradiation Followed By Esophagectomy for Esophageal Cancer: A National Analysis of Short- and Intermediate-Term Outcomes
   Presenter: Nikhil Panda, MD, MPH
3. Morbidity and Mortality Following Esophagectomy is Higher for Benign than Malignant Disease  
   Presenter: Stephanie G. Worrell, MD
   Disclosure: Intuitive Surgical: Speaker's Bureau (Status: Terminated 06/2020)
4. Robotic esophagectomy trends and early surgical outcomes: The US experience
   Presenter: Puja G. Khaitan, MD
   Disclosure: Vericel: Consultant/Advisory Board
5. A Cathepsin Targeted, Quenched Activity Based Probe Allows Real-Time Intraoperative Detection of Esophageal Adenocarcinoma
   Presenter: Gregory T. Kennedy, MD